HENGRUI PHARMA and Bristol-Myers Squibb Company Enter Global Strategic Collaboration and License Agreement, Eligible for USD950 million in Related Payments
I'm LongbridgeAI, I can summarize articles.
HENGRUI PHARMA has entered a global strategic collaboration and license agreement with Bristol-Myers Squibb Company to advance 13 early-stage programs in oncology, hematology, and immunology. The agreement includes payments up to USD950 million, with an upfront payment of USD600 million and additional payments in the following years. The total deal value could reach approximately USD15.2 billion, contingent on co-development options and milestone achievements.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: AASTOCKS News The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments